COVID-19合并肿瘤患者的免疫状态及治疗策略

近期2019新型冠状病毒变异毒株奥密克戎BA.2亚型在全球大流行,对人民的生命安全造成了较大的影响。肿瘤患者因疾病自身或治疗的原因处于免疫失衡状态,更易罹患2019冠状病毒病(coronavirus disease 2019,COVID-19),并且感染后病死率高于正常人群。肿瘤患者和正常人群在感染病毒后免疫状态有所不同,主要表现为两个方面,一方面是各类细胞因子不受调节的过度释放,另一方面是体液免疫和细胞免疫的后继无力,故抗肿瘤治疗策略也应进行相应的调整。现对相关的研究进展做一综述,为这类特殊人群的治疗提供参考。

Immune status of and treatment strategy for patients with tumor and COVID-19

Recently, 2019 novel coronavirus variant strain Omicron BA.2 subtype is in a global pandemic and of great danger to people’s safety. Tumor patients are in a state of immune imbalance due to the disease itself or treatment, so they are more likely to suffer from coronavirus disease 2019 (COVID-19), and the mortality after infection is higher than normal people. Immune status differs between tumor patients and normal population after virus infection, which includes two aspects: one is the unregulated excessive release of various cytokines, and the other is the subsequent weakness of humoral and cellular immunity. Therefore, the anti-tumor treatment strategy should be adjusted accordingly. A review of the relevant research progress is presented to provide reference for the treatment of this special population.